A Phase 4 interventional study of levodopa/carbidopa in Parkinson Disease and Dyskinesias, sponsored by Uppsala University. Completed at 1 site in Sweden. Open to participants aged 30 Years to 90 Years. Per ClinicalTrials.gov, last updated 2009-04-27.
Sponsored by Uppsala University · Phase 4, Interventional, and Treatment
The purpose of this study is to study different kinds of dyskinesias in advanced Parkinson's disease appearing at different levels of levodopa infusion dose. The hypothesis is that different dyskinesias (dystonia, chorea) correlate to different levels of levodopa concentrations, as detected in plasma.
By using duodenal infusion of levodopa/carbidopa, the plasma concentration of levodopa can be kept fairly constant. Different doses, 10-20% higher or lower than the individually optimized dose will be used. Motor performance is captured by video recordings to be compared to/correlated with plasma levodopa concentrations.
4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.
This study's enrollment of 5 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Uppsala University is the lead sponsor of 381 studies on the registry; 84 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: levodopa/carbidopa
Drug: levodopa/carbidopa
Drug: levodopa/carbidopa
Drug: levodopa/carbidopa
Drug: levodopa/carbidopa
intestinal gel, for continuous daytime infusion
Also known as: Duodopa
Correlation between plasma levodopa concentration and choreatic dyskinesia, dystonia, and parkinsonism
Time frame: 3 days
Correlation between choreatic dyskinesia, dystonia, and parkinsonism.
Time frame: 3 days
This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Uppsala University